Eagle Pharmaceuticals, Inc. Comprehensive Income
Eagle Pharmaceuticals, Inc. reported Comprehensive Income of $5.16 million for the 3-month period ending 2023-06-30, per its 10-Q/A filed 2023-08-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2023-08-09
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was $5.16M.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-03-31 was $5.75M, a 87.10% decline year-over-year.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-12-31 was -$2.32M.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-09-30 was -$35.00K.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $34.62M.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$8.72M, a 172.74% decline from fiscal 2020.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was $11.99M, a 16.24% decline from fiscal 2019.
- Eagle Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was $14.31M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-06-30 | $5.16M 10-Q/A · filed 2023-08-09 | $10.91M 10-Q/A · filed 2023-08-09 | $8.59M derived: sum of 3 quarters · filed 2023-08-09 | $8.55M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $5.75M 10-Q · filed 2023-05-09 | $3.43M derived: sum of 2 quarters · filed 2023-05-09 | $3.39M derived: sum of 3 quarters · filed 2023-05-09 | -$4.20M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$2.36M derived: sum of 2 quarters · filed 2023-03-23 | -$9.95M derived: sum of 3 quarters · filed 2023-08-09 | $34.62M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$35.00K 10-Q · filed 2022-11-09 | -$7.62M derived: sum of 2 quarters · filed 2023-08-09 | $36.95M 10-Q · filed 2022-11-09 | $31.54M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-06-30 | -$7.59M 10-Q/A · filed 2023-08-09 | $36.98M 10-Q/A · filed 2023-08-09 | $31.57M derived: sum of 3 quarters · filed 2023-08-09 | $25.98M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $44.57M 10-Q · filed 2023-05-09 | $39.16M derived: sum of 2 quarters · filed 2023-05-09 | $33.56M derived: sum of 3 quarters · filed 2023-05-09 | $36.27M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$11.01M derived: sum of 2 quarters · filed 2023-03-23 | -$8.30M derived: sum of 3 quarters · filed 2023-03-23 | -$8.72M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$5.60M 10-Q · filed 2022-11-09 | -$2.89M derived: sum of 2 quarters · filed 2022-11-09 | -$3.31M 10-Q · filed 2022-11-09 | $4.74M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $2.71M 10-Q · filed 2022-08-09 | $2.29M 10-Q · filed 2022-08-09 | $10.34M derived: sum of 3 quarters · filed 2023-03-23 | $17.40M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | -$421.00K 10-Q · filed 2022-05-09 | $7.64M derived: sum of 2 quarters · filed 2023-03-23 | $14.70M derived: sum of 3 quarters · filed 2023-03-23 | $14.44M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $15.12M derived: sum of 2 quarters · filed 2023-03-23 | $14.86M derived: sum of 3 quarters · filed 2023-03-23 | $11.99M 10-K · filed 2023-03-23 |
| 2020-09-30 | $7.06M 10-Q · filed 2021-11-09 | $6.80M derived: sum of 2 quarters · filed 2021-11-09 | $3.93M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$256.00K 10-Q · filed 2021-08-09 | -$3.13M 10-Q · filed 2021-08-09 | ||
| 2019-12-31 | $14.31M 10-K · filed 2022-03-08 |